Soft-tissue sarcomas in adults

New England Journal of Medicine

Volumn 353, Issue 7, 2005, Pages 701-711

  Clark, Matthew A ^a,b   Fisher, Cyril ^a   Judson, Ian ^a   Meirion Thomas, J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; PACLITAXEL; TRABECTEDIN; VINCRISTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; HISTOLOGY; HUMAN; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SOFT TISSUE SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENETICS; MULTIMODALITY CANCER THERAPY; MUTATION; RADIOTHERAPY; SARCOMA;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RADIOTHERAPY; SARCOMA;

EID: 23844442937     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra041866     Document Type: Review

References (100)

1. Wietz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003;21:2719-25.
2. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. J Bone Joint Surg Am 1996;78:656-63.
3. Ray-Coquard I, Thiesse P, Ranchère-Vince D, et al. Conformity to clinical practice guidelines, multidisciplinary management and outcomes of treatment for soft tissue sarcomas. Ann Oncol 2004;15:307-15.
4. Rydholm A. Centralization of soft tissue sarcoma: the southern Sweden experience. Acta Orthop Scand Suppl 1997;273:4-8.
5. Van Dalen T, Hennipman A, Van Coevorden F, et al. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol 2004;11:483-90.
6. Clasby R, Tilling K, Smith MA, Fletcher CD. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997;84:1692-6.
7. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
8. Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-52.
9. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504-14.
10. Levi F, La Vecchia C, Randimbison L, Te VC. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. Eur J Cancer 1999;35:1711-6.
11. McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med 1995;332:12-8.
12. Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg 1992;127:1379-85.
13. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA 1997;278:1262-7.
14. Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 1992;135:190-9.
15. Rydholm A. Improving the management of soft tissue sarcoma: diagnosis and treatment should be given in specialist centres. BMJ 1998;317:93-4.
16. Demas BE, Heelan RT, Lane J, Marcove R, Hajdu S, Brennan MF. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988;150:615-20.
17. Sanders TG, Parsons TW III. Radiographic imaging of musculoskeletal neoplasia. Cancer Control 2001;8:221-31.
18. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.
19. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-9.
20. Somer EJ, Marsden PK, Benatar NA, Goodey J, O'Doherty MJ, Smith MA. PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques. Eur J Nucl Med Mol Imaging 2003;30:54-62.
21. Vaidya SJ, Payne GS, Leach MO, Pinkerton CR. Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer. Eur J Cancer 2003;39:728-35.
22. Hoeber I, Spillane AJ, Fisher C, Thomas JM. Accuracy of biopsy techniques for limb and limb girdle soft tissue tumors. Ann Surg Oncol 2001;8:80-7.
23. Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 1997;4:425-31.
24. Trovik CS, Bauer HC, Brosjo O, Skoog L, Soderlund V. Fine needle aspiration (FNA) cytology in the diagnosis of recurrent soft tissue sarcoma. Cytopathology 1998;9:320-8.
25. Alvegard TA, Berg NO. Histopathology peer review of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1989;7:1845-51.
26. Clark MA, Thomas JM. Portsite recurrence after laparoscopy for staging of retroperitoneal sarcoma. Surg Laparosc Endosc Percutan Tech 2003;13:290-1.
27. Burkill GJC, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527-32.
28. Fletcher CDM, Unni KK, Mertens F, eds. Pathology and genetics of tumours of soft tissue and bone. Vol. 5 of World Health Organization classification of tumours. Lyon, France: IARC Press, 2002.
29. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-62.
30. Greene FL, Page DL, Fleming ID, et al. eds. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002.
31. Ramanathan RC, A'Hern R, Fisher C, Thomas JM. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 1999;6:57-69.
32. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-89.
33. Stojadinovic A, Leung DH, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol 2002;20:4344-52.
34. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791-6.
35. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
36. Segal NH, Pavlidis NA, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003;163:691-700.
37. Stratton MR, Moss S, Warren W, et al. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 1990;5:1297-301.
38. Kruzelock RP, Hansen MF. Molecular genetics and cytogenetics of sarcomas. Hematol Oncol Clin North Am 1995;9:513-40.
39. Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986-91.
40. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002;62:135-40.
41. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
42. Lee YF, John M, Edwards S, et al. Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 2003;88:510-5.
43. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-7.
44. McCarter MD, Jaques DP, Brennan MF. Randomized clinical trials in soft tissue sarcoma. Surg Oncol Clin N Am 2002;11:11-22.
45. Bowden L, Booher RJ. The principles and technique of resection of soft parts for sarcoma. Surgery 1958;44:963-76.
46. Gerrand CH, Wunder JS, Kandel RA, et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br 2001;83:1149-55.
47. Schwartz DL, Einck J, Bellon J, Laramore GE. Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence. Int J Radiat Oncol Biol Phys 2001;50:449-56.
48. Bickels J, Wittig JC, Kollender Y, Kellar-Graney KL, Malawer MM, Meller I. Sciatic nerve resection: is that truly an indication for amputation? Clin Orthop 2002;399:201-4.
49. Pitcher ME, Thomas JM. Functional compartmental resection for soft tissue sarcomas. Eur J Surg Oncol 1994;20:441-5.
50. Clark MA, Thomas JM. Amputation for soft-tissue sarcoma. Lancet Oncol 2003;4:335-42.
51. Merimsky O, Kollender Y, Inbar M. Is forequarter amputation justified for palliation of intractable cancer symptoms? Oncology 2001;60:55-9.
52. Langstein HN, Robb GL. Reconstructive approaches in soft tissue sarcoma. Semin Surg Oncol 1999;17:52-65.
53. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238:358-71.
54. Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 2000;47:157-63.
55. Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004;100:1943-50.
56. Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas: final results of a prospective, randomized clinical trial. Arch Surg 1993;128:402-10.
57. Lichter AS, Lawrence TS. Recent advances in radiation oncology. N Engl J Med 1995;332:371-9.
58. Strander H, Turesson I, Cavallin-Stahl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol 2003;42:516-31.
59. Janjan N, Crane C, Delclos M, Ballo M. Brachytherapy for locally recurrent soft-tissue sarcoma. Am J Clin Oncol 2002;25:9-15.
60. Tepper JE, Suit HD. Radiation therapy alone for sarcoma of soft tissue. Cancer 1985;56:475-9.
61. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-15.
62. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235-41.
63. Ballo MT, Zagars GK, Cormier JN, et al. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys 2004;58:1461-7.
64. O'Sullivan B, Ward I, Catton C. Recent advances in radiotherapy for soft-tissue sarcoma. Curr Oncol Rep 2003;5:274-81.
65. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: metaanalysis of individual data. Lancet 1997;350:1647-54.
66. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-47.
67. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168-77.
68. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-30.
69. Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001;85:1646-54.
70. Strauss SJ, McTiernan A, Driver D, et al. Single center experience of a new intensive induction therapy for Ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. J Clin Oncol 2003;21:2974-81.
71. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-7.
72. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31.
73. Fata R, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-7.
74. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-7.
75. Eiling S, Lischner S, Busch JO, Rothaupt D, Christophers E, Hauschild A. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol 2002;147:150-3.
76. van Oosterom AT, Mourisden HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002;38:2397-406.
77. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of doseintensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998;21:317-21.
78. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003;12:1843-53.
79. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-9.
80. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
81. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
82. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
83. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
84. Verweij J, Casali PG, Zalcberg J, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): interim results of a randomised phase III trial from the EORTC-STBSG, ISG, and AGITG. Proc Am Soc Clin Oncol 2003;22:814. abstract.
85. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
86. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberansassociated collagen type I alpha1/plateletderived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-B. Cancer Res 1999;59:3719-23.
87. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-6.
88. Gusterson B, Cowley G, McIlhinney J, Ozanne B, Fisher C, Reeves B. Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer 1985;36:689-93.
89. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003;163:1449-56.
90. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004;91:242-7.
91. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
92. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
93. Whooley BP, Gibbs JF, Mooney MM, McGrath BE, Kraybill WG. Primary extremity sarcoma: what is the appropriate follow-up? Ann Surg Oncol 2000;7:9-14.
94. Merimsky O, Kollender Y, Inbar M, Chaitchick S, Meller I. Palliative major amputation and quality of life in cancer patients. Acta Oncol 1997;36:151-7.
95. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993;217:72-7.
96. Behranwala KA, A'Hern R, Omar AM, Thomas JM. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol 2004;11:714-9.
97. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 1999;229:602-12.
98. Temple LKF, Brennan MF. The role of pulmonary metastasectomy in soft tissue sarcoma. Semin Thorac Cardiovasc Surg 2002;14:35-44.
99. Eggermont AMM, de Wilt JHW, ten Hagen TLM. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-37.
100. Sijens PE, Eggermont AM, van Dijk PV, Oudkerk M. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed 1995;8:215-24.